References 1 All responses are informed by Nauck, Michael A et al., Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits, The Lancet, Volume 407, Issue 10531, February 28, 2026, 892 908
Structural and functional analyses, including site-directed mutagenesis and ubiquitination assays, were employed to unravel the molecular interplay between USP15 K39-Kcr and TGFactivated kinase 1 (TAK1)binding proteins 2 (TAB2) stability
Common side effects include mild nausea, vomiting, diarrhea, and constipationmost mild and temporary, especially early in treatment
Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide with semaglutide